Maravai LifeSciences Reports Fourth Quarter and Full Year 20

22.02.2023 - Base business revenues, excluding COVID-19 related CleanCap revenues, were up 67% in the fourth quarter and up 17% for the full year Announces acquisition of privately-held Alphazyme, LLC, adding critical enzyme manufacturing capabilities to ...

Related Keywords

China , United States , America , Maravai Lifesciences , Deb Hart Maravai Lifesciences , Kate Broderick , Sara Michelmore Macdougall , Exchange Commission , Office Of Science , Maravai Lifesciences Holdings Inc , Maravai Topco Holdings , Vector Laboratories Inc , Deloitte Technology Fast , Lifesciences Holdings , Technology Fast , Fastest Growing Companies , North America , Acid Production , Carl Hull , Executive Chairman , Full Year , Months Ended December , Ended December , Nucleic Acid Production , Safety Testing , Maravai Topco , Tax Receivable Agreement , Maravai Lifesciences Holdings , Receivable Agreement , Net Income , Adjusted Fully Diluted Earnings Per , Vector Laboratories , Topco Holdings , Tax Receivable , Earnings Per Share , Adjusted Net Income , Adjusted Diluted , Securities Litigation Reform Act , Annual Report , Quarterly Report , Contact Information , Media Contact , Sara Michelmore Macdougall Advisors ,